Based on the Laurus Labs Limited stock forecast from 3 analysts, the average analyst target price for Laurus Labs Limited is INR 383.00 over the next 12 months. Laurus Labs Limited’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Laurus Labs Limited is Neutral, which is based on 7 positive signals and 8 negative signals. At the last closing, Laurus Labs Limited’s stock price was INR 425.90. Laurus Labs Limited’s stock price has changed by -1.27% over the past week, +7.06% over the past month and +44.13% over the last year.
No recent analyst target price found for Laurus Labs Limited
No recent average analyst rating found for Laurus Labs Limited
Company Overview Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India. Read Less
Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-re...Read More
Frequently Asked Questions About Laurus Labs Limited (LAURUSLABS:NSE) Stock
Based on ratings from 3 analysts Laurus Labs Limited's stock is Buy . Stock Target Advisor's fundamental analysis is Neutral. The stock has 2 buy, 1 sell and hold ratings.
LAURUSLABS:NSE stock's dividend yield is 0.41%.
Our analysis grades LAURUSLABS:NSE stock's dividend yield at F. This means that LAURUSLABS:NSE stock's dividend yield is above 38% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this LAURUSLABS:NSE may be a poor dividend stock for its sector.
Based on targets from 3 analysts, the average taret price for LAURUSLABS:NSE is INR 383.00 over the next 12 months. The maximum analyst target price is INR 440 while the minimum anlayst target price is INR 305.
LAURUSLABS:NSE stock's Price/Earning ratio is 113.72.
Our analysis grades LAURUSLABS:NSE stock's Price / Earning ratio at F. This means that LAURUSLABS:NSE stock's Price/Earning ratio is above 88% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this LAURUSLABS:NSE may be a overvalued for its sector.
The last closing price of LAURUSLABS:NSE's stock was INR 425.90.
The most recent market capitalization for LAURUSLABS:NSE is INR 211.46B.
Based on targets from 3 analysts, the average taret price for LAURUSLABS:NSE is projected at INR 383.00 over the next 12 months.
This means that LAURUSLABS:NSE's stock price may go down by -10.07% over the next 12 months.
Following are ETFs with the highest allocation to Laurus Labs Limited's stock :
As per our most recent records Laurus Labs Limited has 5,753 Employees.
Laurus Labs Limited's registered address is Serene Chambers, Hyderabad, India, 500034.
You can get more information about it from Laurus Labs Limited's website at https://www.lauruslabs.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
What not to like
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for LAURUSLABS:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
